Will primary hypopituitarism in a female lead to low testosterone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, hypopituitarism in females will lead to low testosterone levels.

Women with hypopituitarism consistently demonstrate markedly reduced testosterone levels, with the deficiency being particularly severe when both gonadotropin and ACTH deficiencies are present. 1

Mechanism and Severity

The testosterone deficiency in hypopituitary women results from the loss of both major sources of androgen precursors:

  • Ovarian production (via gonadotropin deficiency - FSH/LH)
  • Adrenal production (via ACTH deficiency)

The most comprehensive recent study using high-sensitivity liquid chromatography-tandem mass spectrometry demonstrated that women with hypogonadotropic hypogonadism had significantly lower levels of 1:

  • Testosterone and dihydrotestosterone
  • Androgen precursors (DHEA, androstenedione)
  • This pattern was consistent in both younger (≤52 years) and older (>52 years) women

Degree of Deficiency Based on Pituitary Involvement

Combined deficiency produces the most severe androgen deficiency: Women with both gonadotropin AND ACTH deficiency had markedly lower concentrations of all sex hormones compared to those with isolated gonadotropin deficiency alone 1, 2. This makes physiologic sense as it eliminates both the ovarian and adrenal sources of testosterone production.

Historical data from 1979 showed plasma testosterone levels of 0.06 ± 0.04 ng/ml in women with panhypopituitarism, compared to normal levels of 0.40 ± 0.10 ng/ml - representing values below 2 standard deviations of normal in all patients 3.

Prevalence

The prevalence of hypoandrogenism in hypopituitary women is substantial:

  • 61% of all women with hypopituitarism have hypoandrogenism
  • 92% of women with ACTH deficiency demonstrate low androgen levels 4

Clinical Implications

This androgen deficiency is not merely a laboratory finding - it contributes to the increased morbidity and mortality observed in hypopituitary women 1, 5, 4. The sex steroid deficiency affects body composition, bone mineral density, cardiovascular risk, and quality of life.

Critical pitfall: Despite the high prevalence and clinical significance, androgen replacement in hypopituitary women remains severely underutilized, with very few women receiving androgen treatment even when documented deficiency exists 4.

References

1
Research

Sex Steroid Levels in Women With Hypopituitarism: A Case-controlled Observational Study.

The Journal of clinical endocrinology and metabolism, 2024

2
Research

Androgen deficiency in women with hypopituitarism.

The Journal of clinical endocrinology and metabolism, 2001

3
Research

Plasma testosterone and the diagnosis of panhypopituitarism in women.

The Journal of clinical endocrinology and metabolism, 1979

Related Questions

What is the appropriate management for a 32-year-old male with hypogonadism, hemoglobin 17.3 g/dL, and estradiol less than 30 pg/mL?
In a 36-year-old well-built asymptomatic male with serial declines in free testosterone that remain within the normal reference range, what is the appropriate next step in management?
In a 40-year-old male with low serum testosterone receiving intramuscular testosterone 25 mg every two weeks and wishing to conceive, does testosterone therapy impair fertility and should it be discontinued?
In a 40-year-old patient receiving 200 mg of testosterone intramuscularly once weekly who continues to have low serum testosterone levels, how should the therapy be optimized?
In a 26-year-old woman with a testosterone level of 72 ng/dL, what does this result indicate?
What reassurance and management should I provide for a patient with a transient reddish‑blue spot after a mosquito bite—no pseudoaneurysm or hematoma—and how should I address the unexpected ER bill?
How should computer vision syndrome be managed, and when is an ophthalmic evaluation indicated?
Is it recommended to prescribe prednisone to a patient with osteoporosis?
In a diabetic patient with peripheral neuropathy and bilateral foot pain, who has dry cracked skin, dystrophic blackened toenails, decreased sensation, bruising, no open wounds, erythema, swelling, warmth, drainage, is afebrile, denies fever or chills, and has malodor without a clear source of infection, should antibiotics be withheld and foot care with podiatry referral and close monitoring be continued while continuing gabapentin 300 mg three times daily for neuropathic pain?
Are women administered midazolam (Versed) more frequently than men before a procedure or surgery?
What is the established elimination half‑life of amiodarone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.